Cannabis Science Inc. Continues Forward with FDA IND Process as Patients Report Successful Cancer Treatments
4/2/2012 10:34:44 AM
DENVER--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech company developing cannabis pharmaceutical and over the counter nutraceutical products, is pleased to report it is moving forward with its FDA IND process. We have kept the public up to date with self-medicated skin cancer patients who are benefiting from topical cannabis-based extracts. These patients have experienced dramatic reduction in tumor burden and for some apparent eradication of their skin cancers.